Valbenazine
والبنازین
🧠 Nervous SystemVMAT2 inhibitor
Market / country: 🇺🇸 USA
Ingrezza (US)
🧮 Dose calculator
Tardive dyskinesia · Regimen source: FDA Ingrezza · 2.1
- • 40 or 60 mg may be considered depending on response and tolerability. FDA Ingrezza · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ History of hypersensitivity to valbenazine (rash, urticaria, angioedema). FDA Ingrezza · 4
Warnings
- • Boxed warning: depression and suicidality in Huntington’s disease; contraindicated with untreated depression or suicidality. FDA Ingrezza · Boxed Warning
- • Somnolence; QT prolongation; neuroleptic malignant syndrome; parkinsonism. FDA Ingrezza · 5
Formulations
- 40 mg capsule — capsule 🇺🇸 USA FDA Ingrezza · 3
- 60 mg capsule — capsule 🇺🇸 USA FDA Ingrezza · 3
- 80 mg capsule — capsule 🇺🇸 USA FDA Ingrezza · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ingrezza · 8.1
“Risk Summary The limited available data on INGREZZA or INGREZZA SPRINKLE use in pregnant women are insufficient to inform a drug-associated risk.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ingrezza · 8.2
“Risk Summary There is no information regarding the presence of valbenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ingrezza · 8.4
“Safety and effectiveness of INGREZZA and INGREZZA SPRINKLE have not been established in pediatric patients.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Ingrezza · 8.5
“No dose adjustment of INGREZZA or INGREZZA SPRINKLE is required for elderly patients.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA209241
- DailyMed (FDA label)FDA Ingrezza
- MedlinePlus (NIH)Valbenazine
- WHO ATC/DDDN07XX13
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Ingrezza · 3FDA Ingrezza · 2.1FDA Ingrezza · 4FDA Ingrezza · Boxed WarningFDA Ingrezza · 5FDA Ingrezza · SPL approval / marketing categoryFDA Ingrezza · 8.1FDA Ingrezza · 8.2FDA Ingrezza · 8.4FDA Ingrezza · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified